[What is reliable in therapy of liver fibrosis?].
Therapy of chronic active liver diseases associated with fibrotic transformation is usually restricted to unspecific antiinflammatory and immunosuppressive agents. However, recent advances in the biochemistry of collagen have allowed to define specific levels of collagen metabolism at which pharmacologic intervention can lead to reduced collagen deposition. The mode of action of some substances which interfere with collagen biosynthesis and degradation is described. However, the efficacy of these agents was tested in vitro exclusively or in animal experiments. Only few agents like colchicine were also studied in clinical trials. Reliable, safe, and specific antifibrotic agents for the clinical management of liver fibrosis do not exist up to now. Advances can be expected, however, from the development of novel inhibitors of prolyl-4-hydroxylase.
Högemann
B
B
Medizinische Klinik und Poliklinik B, Westfälischen Wilhelms-Universität, Münster.
D003094:Collagen / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000473:pathology; D008111:Liver Function Tests; D003012:Microbial Collagenase / Q000378:metabolism; D011347:Procollagen / Q000037:antagonists & inhibitors; D011393:Procollagen-Proline Dioxygenase / Q000037:antagonists & inhibitors
D011347:Procollagen; D003094:Collagen; D011393:Procollagen-Proline Dioxygenase; D003012:Microbial Collagenase
Was ist gesichert in der Therapie der Leberfibrose?